Ionis Pharmaceuticals/$IONS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Ticker
$IONS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,069
ISIN
US4622221004
Website
IONS Metrics
BasicAdvanced
$6.8B
-
-$3.00
0.29
-
Price and volume
Market cap
$6.8B
Beta
0.29
52-week high
$52.34
52-week low
$23.95
Average daily volume
1.9M
Financial strength
Current ratio
9.664
Quick ratio
8.742
Long term debt to equity
408.824
Total debt to equity
413.8
Interest coverage (TTM)
-4.95%
Profitability
EBITDA (TTM)
-460.854
Gross margin (TTM)
-25.26%
Net profit margin (TTM)
-63.86%
Operating margin (TTM)
-65.75%
Effective tax rate (TTM)
1.31%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
-10.59%
Return on equity (TTM)
-118.53%
Valuation
Price to revenue (TTM)
9.112
Price to book
14.32
Price to tangible book (TTM)
14.32
Price to free cash flow (TTM)
-11.687
Free cash flow yield (TTM)
-8.56%
Free cash flow per share (TTM)
-366.49%
Growth
Revenue change (TTM)
-7.64%
Earnings per share change (TTM)
12.09%
3-year revenue growth (CAGR)
-5.16%
10-year revenue growth (CAGR)
11.19%
3-year earnings per share growth (CAGR)
377.35%
10-year earnings per share growth (CAGR)
30.66%
What the Analysts think about IONS
Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.
Bulls say / Bears say
Ionis Pharmaceuticals secured FDA approval for Tryngolza (olezarsen) in December 2024, marking its first independent drug launch and potentially opening new revenue streams. (Wikipedia)
Positive interim Phase 1 results for salanersen (ION306/BIIB115) in treating spinal muscular atrophy have led Biogen to plan Phase 3 studies, indicating strong pipeline progress. (StockTitan)
Analysts have raised the price target for Ionis Pharmaceuticals to $77, citing encouraging early data for its Angelman syndrome treatment, IONS582. (Investing.com)
Ionis Pharmaceuticals announced a $500.3 million public offering in September 2024, leading to a 12% stock price drop due to potential shareholder dilution. (Nasdaq)
StockNews.com downgraded Ionis Pharmaceuticals to a 'Sell' rating in October 2024, reflecting concerns about the company's performance. (ETF Daily News)
Ionis Pharmaceuticals discontinued development programs for ION541 for ALS and IONIS-FB-LRx for geographic atrophy, raising concerns about pipeline setbacks. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
IONS Financial Performance
Revenues and expenses
IONS Earnings Performance
Company profitability
IONS News
AllArticlesVideos
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Business Wire·2 weeks ago
Ionis to host 2025 virtual Annual Meeting of Stockholders
Business Wire·2 months ago
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals (IONS) has a market cap of $6.8B as of July 11, 2025.
What is the P/E ratio for Ionis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ionis Pharmaceuticals (IONS) stock is 0 as of July 11, 2025.
Does Ionis Pharmaceuticals stock pay dividends?
No, Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Ionis Pharmaceuticals dividend payment date?
Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders.
What is the beta indicator for Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.